Last $81.98 USD
Change Today +0.66 / 0.81%
Volume 944.1K
SYK On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 08/19/14 All times are local (Market data is delayed by at least 15 minutes).

stryker corp (SYK) Snapshot

Open
$81.25
Previous Close
$81.32
Day High
$82.02
Day Low
$81.08
52 Week High
06/20/14 - $86.93
52 Week Low
08/29/13 - $66.44
Market Cap
31.0B
Average Volume 10 Days
1.2M
EPS TTM
$4.21
Shares Outstanding
378.6M
EX-Date
09/26/14
P/E TM
19.5x
Dividend
$1.22
Dividend Yield
1.44%
Current Stock Chart for STRYKER CORP (SYK)

stryker corp (SYK) Details

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. The company operates in three segments: Reconstructive, MedSurg, and Neurotechnology and Spine. The Reconstructive segment provides orthopaedic reconstructive implants used in hip and knee joint replacements; and trauma systems, as well as other related products. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling and emergency medical equipment, and reprocessed and remanufactured medical devices, as well as other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurosurgical and neurovascular devices that include products for use in invasive endovascular techniques, products for traditional brain and open skull base surgical procedures, and orthobiologic and biosurgery products, as well as products for the treatment of acute ischemic and hemorrhagic stroke. This segment also develops, manufactures, and markets spinal implant products, including cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company markets its products to doctors, hospitals, and other healthcare facilities in the United States, as well as sells its products through local dealers, direct sales, and third-party dealers and distributors in approximately 100 countries worldwide. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

25,000 Employees
Last Reported Date: 02/13/14
Founded in 1941

stryker corp (SYK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.0M
Chief Financial Officer and Vice President
Total Annual Compensation: $431.4K
Group President of Global Quality & Operation...
Total Annual Compensation: $407.4K
Group President of Medsurg and Neurotechnolog...
Total Annual Compensation: $553.3K
Group President of International
Total Annual Compensation: $512.5K
Compensation as of Fiscal Year 2013.

stryker corp (SYK) Key Developments

Stryker Corporation Announces Board Changes

Stryker Corporation announced that Kevin A. Lobo, President and Chief Executive Officer, has been appointed Chairman of the Board, in addition to his current responsibilities, effective July 22, 2014. William U. Parfet, Stryker's Non-Executive Chairman, will again assume the role of Lead Independent Director. Mr. Lobo joined Stryker in April 2011 and served as Group President of Stryker Orthopaedics prior to his appointment as President and Chief Executive Officer in October, 2012.

Stryker Corporation Declares Quarterly Dividend, Payable on October 31, 2014

Stryker Corporation announced that its Board of Directors has maintained a dividend consistent with that of the prior quarter, by declaring a quarterly dividend of $0.305 per share payable on October 31, 2014, to shareholders of record at the close of business on September 30, 2014. This represents an increase of 15% compared to the prior year.

Stryker Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter and Full Year 2014 and Full Year 2015

Stryker Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's net sales rose 6.8% year over year to $2.4 billion. GAAP net income rose $215 million, or $0.56 per share, up 0.9% over the year-ago profit of $213 million. Excluding one-time items, including charges related to product recalls of its Rejuvenate and ABG II artificial hips as well as its Neptune waste-fluid collector system, along with litigation and restructuring charges, its adjusted net income rose to $415 million, or $1.08 per share. Operating income was $307 million against $290 million a year ago. Earnings before income taxes were $277 million against $269 million a year ago. Net cash provided by operating activities was $366 million against $356 million a year ago. Purchases of property, plant and equipment was $54 million against $47 million a year ago. Adjusted operating income was $565 million against $552 million a year ago.  For the six months, the company's net sales were $4,668 million against $4,402 million a year ago. Operating income was $438 million against $676 million a year ago. Earnings before income taxes were $384 million against $644 million a year ago. Net earnings were $285 million or $0.74 diluted per share against $517 million or $1.35 diluted per share a year ago. Net cash provided by operating activities was $572 million against $592 million a year ago. Purchases of property, plant and equipment was $124 million against $96 million a year ago. Adjusted operating income was $1,121 million against $1,086 million a year ago. Net earnings were $819 million or $2.14 diluted per share against $823 million or $2.16 diluted per share a year ago. For the third quarter 2014, the company projects adjusted EPS of $1.12 to $1.16, excluding amortization of intangible assets. For the full year 2014, the company projects adjusted EPS of $4.75 to $4.80. Revenue is seen growing 5% to 6% over year-ago levels, excluding amortization of intangible assets. For the full year 2015, the company expects effective tax rate to improve by roughly 2 percentage points or $0.10 to $0.15 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SYK:US $81.98 USD +0.66

SYK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $118.22 USD +0.32
Covidien PLC $88.44 USD +0.72
Ecolab Inc $113.82 USD +0.42
Olympus Corp ¥3,620 JPY +30.00
St Jude Medical Inc $64.55 USD +0.39
View Industry Companies
 

Industry Analysis

SYK

Industry Average

Valuation SYK Industry Range
Price/Earnings 45.3x
Price/Sales 3.3x
Price/Book 3.4x
Price/Cash Flow 36.3x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STRYKER CORP, please visit www.strykercorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.